NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is to improve the standard of care for patients with Benign Prostatic Hyperplasia (BPH), a broadly underserved market. Our first product is the UroLift® System, a minimally invasive device designed to treat lower urinary tract symptoms (LUTS) due to BPH.
BPH is a common condition that affects over 500 million aging men worldwide.1,2 Causing bothersome, chronic lower urinary tract symptoms, BPH can cause loss of productivity, loss of sleep, depression and decreased quality of life.3 For patients with moderate-severe symptoms, medication is often the first-line therapy.4 However, with side-effects such as sexual dysfunction, dizziness and headaches along with inadequate relief, over one-quarter of patients discontinue medical therapy, often after only three months.5 For these patients, the next alternative is surgery. Most surgical approaches aim to resect or ablate prostate tissue in order to open up the blocked urethra.
While effective in opening up the urethra and relieving symptoms, resecting or ablating prostate tissue also induces a healing response and tissue inflammation. As a result, patients have to 'earn' their symptom relief after a difficult period of irritative voiding symptoms and catheterization.6,7 Long-term, even the 'gold standard' surgery, TURP (transurethral resection of the prostate), can leave patients with unwelcome permanent side-effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).6,7
The UroLift System is a minimally invasive device designed to open the urethra directly without the need to resect or ablate prostate tissue. Deployed through the UroLift Delivery Device, permanent UroLift Implants are placed transurethrally to retract the obstructing prostatic lobes while leaving the prostate intact. Click here to learn more about the UroLift System.
NeoTract, Inc. was founded in 2004 through the ExploraMed Development, LLC medical device incubator funded by New Enterprise Associates. The Company's headquarters are in Pleasanton,